Canadian urological association

Federal government canadian urological association often end in. The site is secure. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. Inan estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate.

Canadian urological association

McMaster Institute of Urology at St. Published: Robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction A retrospective review of a high-volume Canadian center Michael Ordon, Aren Mnatzakanian, Melody Djuimo, R. Vangala, Mohammed Bassuony, Ahmed S. Zakaria, Walid Shahrour, Hazem Elmansy. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience Hanbo Zhang, Nimira S. Alimohamed, Naveen S. Stenson, Douglas A. Stewart, Christopher P. Venner, Peter Venner, Michael P. Complication rates of ciprofloxacin alone vs. Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy Jun Teishima, Junichiro Hirata, Takuya Toge, Riku Uematsu, Yoshie Mita, Takahiko Yoshii, Ichiro Nakamura. Sfakianos, Tracy L.

Barriers to incorporating social media that were mentioned by respondents included unclear advantage, a lack of time to set up and manage, and privacy concerns, canadian urological association. Future surveys will also be invaluable in tracking the impact of changes on urological care as a result of changes in healthcare delivery and general population demographic shifts. The CUA once again endorses these recommendations, with some added practical considerations.

Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. McMaster Institute of Urology at St.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate. Privacy Policy.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October

Spruceeats

As such, for these men, continued PSA testing is a matter of clinical judgment and personal preferences. Conclusion Population-based screening has demonstrated benefits in reducing prostate cancer mortality; however, decisions to proceed with screening should be based upon shared decision-making, recognizing that each patient has a different perspective with regards to the potential benefits and harms of prostate cancer screening and treatment. Stenson, Douglas A. Several prostate cancer risk nomograms have been developed to aid in the detection of clinically significant prostate cancer. Members who had not responded to the online survey and were in attendance at the CUA annual meeting in Charlottetown, PEI, had the opportunity to complete the survey using computers provided at the meeting. The information obtained from this in-depth survey of the CUA membership can be used by the organization and its committees in a number of ways. Preventive Services Task Force recommendations against prostate-specific antigen screening on prostate biopsy and cancer detection rates. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Impact of the U. The site is secure.

Federal government websites often end in. The site is secure.

Second, in order to identify studies not captured by existing guidelines, a search of the literature was conducted using MEDLINE to identify articles related to the screening and diagnosis of prostate cancer that were published between January 1, and February 2, The CUA active membership survey has provided an invaluable snapshot on the state of urology in Canada. Twitter Tweets by CanUrolAssoc. In particular, men in the screening arms of the ERSPC trial and Goteborg trial underwent testing at intervals of four and two years, respectively, providing the basis for our recommendations. Best screening practices When prostate cancer screening is performed, the overarching goal should be the early detection of clinically significant prostate cancer in healthy men while minimizing the detection and treatment of low-risk disease. In the six nomograms with adequate validation across several study populations, the discrimination properties for prostate cancer detection were moderate AUC 0. What diagnostic tests, in addition to prostate-specific antigen PSA , are available for the early diagnosis of prostate cancer? In these cases, an individualized testing strategy after consultation with a clinical geneticist is most appropriate. A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Apr 28, J Urol. This is apparent in both the biopsy-naive setting and in men with a prior negative biopsy. Appendix 1 Search string relating to prostate-specific antigen screening. J Clin Oncol. At the present time, based upon the available data, the CUA does not encourage the widespread use of these tests.